Dr. Howard Lawrence Levitt, MD

Dr. Levitt practices at Robert Wood Johnson University Hospital Rahway in Rahway, New Jersey, part of RWJBarnabas Health.

Dr. Levitt's NPI, 1437341922, was assigned on August 17, 2007. Dr. Levitt graduated from University of Missouri, Columbia School of Medicine in 2002. Dr. Levitt holds New York license 246484.

Dr. Levitt's primary practice is Robert Wood Johnson University Hospital Rahway, at 865 Stone St, Rahway, NJ 07065 in Union County. The practice phone is (732) 381-4200.

Dr. Levitt's primary practice is Robert Wood Johnson University Hospital Rahway in Rahway, New Jersey, part of RWJBarnabas Health. Dr. Levitt is also affiliated with Cooperman Barnabas Medical Center. The medical group on file is RWJBarnabas Health Medical Group. Dmand AI also links Dr. Levitt to 2 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Levitt practices, 4 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Levitt's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Levitt is licensed in New York.

CMS data shows 972 Medicare services from Dr. Levitt across 8 procedure codes in 2024, for 540 Medicare patients. Medicare paid $54,891 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 540 Medicare patients who saw Dr. Levitt in 2024. The largest group is 75 to 84, with 179 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Levitt's median patient age at 71, with 51% women.

In 2024, Dr. Levitt wrote 402 Medicare Part D claims for 69 patients. 84% of them were for generic drugs. CMS names the drug for 300 of them, across 12 drugs with 11 or more claims each, at $32,093 in total drug cost. In 2023, CMS named 173 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Levitt for performance year 2024, reported through an alternative payment model (APM). Dr. Levitt accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 111 general payments to Dr. Levitt from 30 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 66% of the total. Abbott Laboratories paid the most, $1,302.

Dr. Levitt graduated from University of Missouri, Columbia School of Medicine in 2002.